Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

Purpose: Pancreatic ductal adenocarcinoma (PDAC) with difficulty in early diagnosis does not respond well to conventional treatments and has not occurred significant improvement in the overall 5-year survival rates. Mesothelin (MSLN) is a tumor differentiation antigen expressed in several solid neop...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Kai, Wang, Jia, Zhang, Tao, Guo, Yifan, Chang, Hong, Wang, Siyuan, Zhu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053310/
https://www.ncbi.nlm.nih.gov/pubmed/32174772
http://dx.doi.org/10.7150/ijms.39012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053310/
https://www.ncbi.nlm.nih.gov/pubmed/32174772
http://dx.doi.org/10.7150/ijms.39012

Ejemplares similares